$67.07-0.33 (-0.49%)
BXP, Inc.
BXP, Inc. in the Real Estate sector is trading at $67.07 with a market capitalization of $11.8B. Wall Street consensus targets $69.65 (20 analysts), implying a +3.8% move over the next 12 months. The stock is currently 15% below its 52-week high of $79.33, remaining 5.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $872.15M↓ | $877.10M↑ | $871.51M↑ | $868.46M↑ | $865.22M |
| Gross Profit | $520.08M↓ | $528.36M↓ | $530.15M↑ | $527.03M↑ | $526.07M |
| Operating Income | $227.91M↓ | $254.59M↑ | $253.99M↓ | $256.59M↑ | $249.18M |
| Net Income | $101.58M↓ | $248.35M↑ | -$121.71M↓ | $88.98M↑ | $61.18M |
BXP, Inc. (BXP) is the largest publicly traded developer, owner, and manager of premier workplaces in the United States. Also, concentrated in six dynamic gateway markets - Boston, Los Angeles, New York, San Francisco, Seattle, and Washington, DC. BX...
BXP, Inc. (NYSE:BXP) is one of the 10 Interest Rate Sensitive Stocks to Buy Now. On June 18, 2026, Scotiabank upgraded BXP, Inc. (BXP) to Outperform from Sector Perform with a price target of $70, up from $65. Scotiabank said leasing has been strong since the company’s investor day last September, which should help improve […]
BXP signs a long-term 320,000-square-foot lease with Boston Dynamics at Reservoir Place. This represents one of Greater Boston's largest innovation office deals this year.
Although BXP has underperformed the broader Nasdaq Composite over the past year, analysts remain moderately bullish on the stock's outlook.
BXP's 343 Madison gains momentum as a major law firm lease lifts pre-leasing to 56%, supporting its premium-office strategy and 2026 outlook.
Alexandria Real Estate is underperforming the Dow, as uneven returns and cautious analyst sentiment overshadow its niche life science strength.